Skip to main content
Premium Trial:

Request an Annual Quote

Metamark Genetics Buys HealthTronics' Anatomical Pathology Business

NEW YORK (GenomeWeb News) – Endo Health Solutions said late on Monday that its wholly owned subsidiary HealthTronics has sold its anatomical pathology business to Metamark Genetics for an undisclosed amount.

The business called HealthTronics Laboratory Solutions provides anatomical pathology services mainly to the urology community. Its labs are located in Georgia and Pennsylvania. It also manages pathology laboratories for physician practice groups, provides administrative services to in-office pathology labs for physical practice groups, and provides pathology services to physicians.

The sale of HealthTronics HLS comes as Endo Health pursues strategic alternatives for HealthTronics.

Metamark, based in Cambridge, Mass., develops prognostic and diagnostic tests for cancer using genomic and proteomic technologies. It plans to commercialize its ProMark prognostic prostate cancer test in 2013 through its CLIA laboratory.

In a statement Metamark President and CEO Shawn Marcell said "joining forces with HLS will be instrumental to our success" when it launches the ProMark test.

In November, Metamark raised $13 million in a Series B financing round as Mark Straley resigned as the company's president and CEO.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.